Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

714

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Metastatic Castrate Resistant Prostate Cancer
Interventions
DRUG

Masitinib

DRUG

Docetaxel

DRUG

Prednisone

DRUG

Placebo

Trial Locations (9)

13001

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

20141

Istituto Europeo di Oncologia, Milan

33081

Centro di Riferimento Oncologico, Aviano

54100

Polyclinique d'oncologie de Gentilly, Nancy

56100

Azienda Ospedaliero Universitaria Pisana, Pisa

59100

Universiti Malaya Medical Centre, Kuala Lumpur

197136

Clinic Andros LLC, Saint Petersburg

226014

Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow

644013

Clinical Oncology Dispensary, Omsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AB Science

INDUSTRY